Themis Medicare Ltd

Themis Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable shift in its financial trajectory for the quarter ended March 2026. Despite a decline in net sales, the company posted significant profit growth, signalling a positive change in its financial trend after a period of stagnation.

Themis Medicare Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹1,055.47 crores, has posted a consolidated net profit of ₹8.89 crores for Q4 FY26 (Mar'26 quarter), marking an 11.89% sequential decline from ₹10.09 crores in Q3 FY26 but a dramatic turnaround from a loss of ₹9.66 crores in the year-ago quarter. The stock has responded positively to recent trading momentum, gaining 13.88% over the past week to close at ₹114.60 on May 29, 2026, though it remains 18.14% below its level from a year ago.

Themis Medicare Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 Apr 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 May 2026, providing investors with the latest insights into its performance and outlook.

Themis Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Themis Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Themis Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Themis Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 6 April 2026, reflecting a nuanced shift in its technical outlook despite persistent financial headwinds. This change is driven primarily by improvements in technical indicators, while fundamental and valuation metrics continue to weigh on the stock’s prospects.

Themis Medicare Ltd has exhibited a subtle shift in price momentum, moving from a bearish to a mildly bearish technical trend, reflecting a nuanced change in investor sentiment. Despite a modest day gain of 1.84%, the stock remains under pressure with mixed signals from key technical indicators such as MACD, RSI, and moving averages, underscoring a cautious outlook for this micro-cap pharmaceutical player.

A sharp decline in Themis Medicare Ltd has pushed the stock to a fresh 52-week low of Rs 68.15 on 30 Mar 2026, marking a continuation of recent losses that have seen the share price fall by 7.53% over the last two sessions. This drop comes amid a broader market downturn, but the stock’s underperformance is notably more severe than the benchmark indices.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

A sharp decline of 7.58% in intraday trading dragged Themis Medicare Ltd to a fresh 52-week low of Rs 69.5 on 27 Mar 2026, extending its downward spiral amid broader market weakness.

A sharp decline of over 60% from its 52-week high has dragged Themis Medicare Ltd to a fresh 52-week low of Rs 70.52 on 24 Mar 2026, underscoring persistent selling pressure amid deteriorating fundamentals and subdued market sentiment.

A sharp decline of 4.17% today dragged Themis Medicare Ltd to a fresh 52-week low of Rs 72.39, extending a downward trajectory that has seen the stock lose over half its value in the past year.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 Feb 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 19 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.